3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Recurrence
8
Lung Neoplasms
6
Neoplasm Metastasis
5
Lymphoma, T-Cell, Peripheral
4
Breast Neoplasms
4
Neoplasms
3
Lymphoma, T-Cell
3
Urinary Bladder Neoplasms
2
Stomatitis
2
Sezary Syndrome
2
Papillomavirus Infections
2
Nasopharyngeal Carcinoma
2
Mycosis Fungoides
2
Meningeal Carcinomatosis
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, B-Cell
2
Lymphoma
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Anemia
2
Waldenstrom Macroglobulinemia
1
Vitamin B 12 Deficiency
1
Ureteral Neoplasms
1
Thyroid Diseases
1
Thrombocytopenia
1
Stroke
1
Stomach Neoplasms
1
Smoking
1
Prostatic Neoplasms
1
Interventions
Gemcitabine
679
130-nm albumin-bound paclitaxel
198
Fluorouracil
186
Oxaliplatin
175
Albumin-Bound Paclitaxel
151
Capecitabine
137
Leucovorin
131
Irinotecan
113
Radiotherapy
95
Taxes
83
pembrolizumab
80
Cisplatin
72
Erlotinib Hydrochloride
69
Radiosurgery
67
Nivolumab
56
Bevacizumab
54
Drug Therapy
52
Cyclophosphamide
49
Magnetic Resonance Spectroscopy
46
folfirinox
42
Docetaxel
41
Cetuximab
40
Specimen Handling
37
irinotecan sucrosofate
36
S 1 (combination)
36
Biopsy
31
Radiation
29
Paclitaxel
29
Ipilimumab
27
durvalumab
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Neoplasms
×
Vitamin B 12
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled